The Management Board of MEDINICE S.A., headquartered in Warsaw (the"Company"), announces that on March 7, 2025, it received informationelectronically from the Management Board of the Mazovian Voivodeshipregarding the adoption of a resolution approving the evaluation resultsof the Company's application for funding under the European FundsProgram for Mazovia 2021-2027. The application falls under the Priority- European Funds for a More Competitive and Intelligent Mazovia, Action- Research, Development, and Innovation for Enterprises, with the callnumber:FEMA.01.01-IP.01-013/24

As a result of an independent evaluation conducted by the ProjectEvaluation Committee (KOP), theAtriClampproject received a positive assessment in both access criteria andgeneral substantive criteria. Consequently, the project, titled"AtriClamp- an innovative system for left atrial appendage occlusion (LAAO),"has been selected for funding in the amount ofPLN8,707,055.